DK2322603T3 - Sammensætninger og fremgangsmåder til aktivering af monocytiske dendritiske celler og t-celler for th1-respons - Google Patents

Sammensætninger og fremgangsmåder til aktivering af monocytiske dendritiske celler og t-celler for th1-respons Download PDF

Info

Publication number
DK2322603T3
DK2322603T3 DK10181985.2T DK10181985T DK2322603T3 DK 2322603 T3 DK2322603 T3 DK 2322603T3 DK 10181985 T DK10181985 T DK 10181985T DK 2322603 T3 DK2322603 T3 DK 2322603T3
Authority
DK
Denmark
Prior art keywords
cells
activating
compositions
response
methods
Prior art date
Application number
DK10181985.2T
Other languages
English (en)
Inventor
Marnix L Bosch
Original Assignee
Northwest Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Northwest Biotherapeutics Inc filed Critical Northwest Biotherapeutics Inc
Application granted granted Critical
Publication of DK2322603T3 publication Critical patent/DK2322603T3/da

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/57—IFN-gamma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/70—Undefined extracts
    • C12N2500/72—Undefined extracts from bacteria
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
DK10181985.2T 2001-09-06 2002-09-06 Sammensætninger og fremgangsmåder til aktivering af monocytiske dendritiske celler og t-celler for th1-respons DK2322603T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31759201P 2001-09-06 2001-09-06
EP02761594.7A EP1441591B1 (en) 2001-09-06 2002-09-06 Compositions and methods for priming monocytic dendritic cells and t cells for th-1 response

Publications (1)

Publication Number Publication Date
DK2322603T3 true DK2322603T3 (da) 2020-01-27

Family

ID=32654226

Family Applications (2)

Application Number Title Priority Date Filing Date
DK10181985.2T DK2322603T3 (da) 2001-09-06 2002-09-06 Sammensætninger og fremgangsmåder til aktivering af monocytiske dendritiske celler og t-celler for th1-respons
DK02761594.7T DK1441591T3 (da) 2001-09-06 2002-09-06 Sammensætninger og fremgangsmåder til priming af monocytiske dendritiske celler og T-celler for TH-1-respons

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02761594.7T DK1441591T3 (da) 2001-09-06 2002-09-06 Sammensætninger og fremgangsmåder til priming af monocytiske dendritiske celler og T-celler for TH-1-respons

Country Status (18)

Country Link
US (2) US20050059151A1 (da)
EP (3) EP3653055A1 (da)
JP (3) JP2005505270A (da)
KR (3) KR20110081341A (da)
CN (2) CN102973928B (da)
AU (1) AU2008221592B2 (da)
BR (1) BRPI0212545B8 (da)
CA (1) CA2459713C (da)
DK (2) DK2322603T3 (da)
ES (2) ES2598109T3 (da)
HK (1) HK1079989A1 (da)
IL (3) IL160720A0 (da)
MX (1) MXPA04002147A (da)
NO (2) NO338147B1 (da)
NZ (1) NZ531530A (da)
PL (1) PL372098A1 (da)
PT (2) PT2322603T (da)
WO (1) WO2003022215A2 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT412145B (de) * 2002-09-13 2004-10-25 Forsch Krebskranke Kinder Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
US20040057935A1 (en) * 2002-09-20 2004-03-25 Cedars-Sinai Medical Center Intratumoral delivery of dendritic cells
KR101144196B1 (ko) * 2002-12-06 2012-05-21 노쓰웨스트 바이오써라퓨틱스, 인크. 종양 치료를 위한 시험관내 부분 성숙된 수지상 세포를 포함하는 조성물
EP1604016B1 (en) * 2003-02-27 2009-01-14 NorthWest Biotherapeutics, Inc. Generation of dendritic cells from monocytic dendritic precursor cells with gm-csf in the absence of additional cytokines
EP1484064A1 (en) 2003-06-04 2004-12-08 Gesellschaft für Biotechnologische Forschung Therapeutical composition containing dentritic cells and use thereof
EP1670513B1 (en) * 2003-10-06 2013-01-23 Cedars-Sinai Medical Center Cox-2 inhibitors and dendritic cells for use in the treatment of cancer.
WO2005043155A1 (en) * 2003-10-21 2005-05-12 Cedars-Sinai Medical Center System and method for the treatment of cancer, including cancers of the central nervous system
EP1690937B1 (en) * 2003-11-04 2012-10-17 Dnavec Research Inc. Method of constructing transgenic dendritic cell
AU2005257107A1 (en) 2004-06-24 2006-01-05 Dnavec Research Inc. Anticancer agent containing dendritic cell having RNA virus transferred thereinto
EP3805367A1 (en) * 2005-12-08 2021-04-14 NorthWest Biotherapeutics, Inc. Compositions and methods for inducing the activation of immature monocytic dendritic cells
EP1840206A1 (en) * 2006-03-28 2007-10-03 Gsf-Forschungszentrum Für Umwelt Und Gesundheit, Gmbh Compositions for the preparation of mature dendritic cells
CA2700573C (en) 2006-09-26 2016-11-22 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
WO2008039974A2 (en) 2006-09-28 2008-04-03 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
PL2328923T3 (pl) 2008-09-02 2016-06-30 Cedars Sinai Medical Center Epitopy CD133
US8383768B2 (en) * 2009-05-07 2013-02-26 Immunocellular Therapeutics, Ltd. CD133 epitopes
SG11201404543UA (en) * 2012-02-02 2014-08-28 California Stem Cell Inc Pluripotent germ layer origin antigen presenting cancer vaccine
JP6134785B2 (ja) * 2012-05-31 2017-05-24 ジェイダブリュ クレアジェン インコーポレイテッド 樹状細胞成熟化組成物、およびこれを用いて抗原特異的樹状細胞を製造する方法
AU2020203845C1 (en) * 2012-09-06 2022-08-11 Orbis Health Solutions, Llc Tumor lysate loaded particles
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
AU2013359392C1 (en) 2012-12-12 2016-12-08 Orbis Health Solutions, Llc Compositions and methods for tissue regeneration
WO2014127296A1 (en) 2013-02-14 2014-08-21 Immunocellular Therapeutics, Ltd Cancer vaccines and vaccination methods
CN112891522A (zh) * 2013-09-05 2021-06-04 奥比思健康解决方案有限责任公司 装载了肿瘤裂解物的微粒
EP3932392A1 (en) 2014-03-05 2022-01-05 Orbis Health Solutions LLC Vaccine delivery systems using yeast cell wall particles
US9972054B1 (en) 2014-05-20 2018-05-15 State Farm Mutual Automobile Insurance Company Accident fault determination for autonomous vehicles
US10373259B1 (en) 2014-05-20 2019-08-06 State Farm Mutual Automobile Insurance Company Fully autonomous vehicle insurance pricing
US9646428B1 (en) 2014-05-20 2017-05-09 State Farm Mutual Automobile Insurance Company Accident response using autonomous vehicle monitoring
US10599155B1 (en) 2014-05-20 2020-03-24 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US11669090B2 (en) 2014-05-20 2023-06-06 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation feature monitoring and evaluation of effectiveness
US9786154B1 (en) 2014-07-21 2017-10-10 State Farm Mutual Automobile Insurance Company Methods of facilitating emergency assistance
US10831204B1 (en) 2014-11-13 2020-11-10 State Farm Mutual Automobile Insurance Company Autonomous vehicle automatic parking
CN114774356A (zh) * 2015-06-30 2022-07-22 西北生物治疗药物公司 诱发改善的或增加的抗肿瘤免疫应答的经最佳活化的树突细胞
EP3317402B1 (en) 2015-06-30 2024-02-14 Universidade Nova de Lisboa A viable cell population, method for production and uses thereof
US11107365B1 (en) 2015-08-28 2021-08-31 State Farm Mutual Automobile Insurance Company Vehicular driver evaluation
US10324463B1 (en) 2016-01-22 2019-06-18 State Farm Mutual Automobile Insurance Company Autonomous vehicle operation adjustment based upon route
US10818105B1 (en) 2016-01-22 2020-10-27 State Farm Mutual Automobile Insurance Company Sensor malfunction detection
US10395332B1 (en) 2016-01-22 2019-08-27 State Farm Mutual Automobile Insurance Company Coordinated autonomous vehicle automatic area scanning
US11242051B1 (en) 2016-01-22 2022-02-08 State Farm Mutual Automobile Insurance Company Autonomous vehicle action communications
US11441916B1 (en) 2016-01-22 2022-09-13 State Farm Mutual Automobile Insurance Company Autonomous vehicle trip routing
US10134278B1 (en) 2016-01-22 2018-11-20 State Farm Mutual Automobile Insurance Company Autonomous vehicle application
US11719545B2 (en) 2016-01-22 2023-08-08 Hyundai Motor Company Autonomous vehicle component damage and salvage assessment
KR102038114B1 (ko) * 2016-02-26 2019-10-30 주식회사 엘지화학 광학 점착제용 (메타)아크릴레이트기 함유 벤조페논의 제조방법 및 광학 점착제 조성물
US12059434B2 (en) 2017-02-28 2024-08-13 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Short-term activated DC1s and methods for their production and use
KR20220098351A (ko) * 2019-10-07 2022-07-12 노쓰웨스트 바이오써라퓨틱스, 인크. 수지상 세포 및 T 세포의 활성화를 증진시키고 Th-1 면역 반응을 유도하기 위한 시험관내 방법 및 조성물

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
US5366866A (en) * 1991-07-25 1994-11-22 Duke University Method of diagnosing ovarian and endometrial cancer with monoclonal antibodies OXA and OXB
US5227471A (en) * 1992-01-30 1993-07-13 Eastern Virginia Medical School Of The Medical College Of Hampton Roads Monoclonal antibody PD41 that binds to a prostate mucin antigen that is expressed in human prostatic carcinoma
US5788963A (en) 1995-07-31 1998-08-04 Pacific Northwest Cancer Foundation Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
CN1172718C (zh) * 1995-10-04 2004-10-27 依默耐克斯有限公司 树突状细胞刺激因子
US7659119B2 (en) * 1996-02-12 2010-02-09 Argos Therapeutics, Inc. Method and compositions for obtaining mature dendritic cells
EP2058389B1 (en) * 1997-10-27 2016-05-18 Rockefeller University Defined dendritic cell maturation medium comprising TNF-alpha, IL-1beta, IL-6
JP2000143534A (ja) * 1998-11-13 2000-05-23 Asahi Chem Ind Co Ltd 樹状細胞ワクチン及びその製造方法
JP2000279181A (ja) * 1999-04-01 2000-10-10 Japan Science & Technology Corp ヒト樹状細胞の発現遺伝子群
EP1254953A4 (en) * 1999-12-28 2004-06-02 Toyoshima Kumao Maturity-triggering agent for immature dendritic cells
US6247378B1 (en) * 2000-01-06 2001-06-19 Deere & Company Operator control device for an infinitely variable transmission
ES2571979T3 (es) * 2000-05-12 2016-05-27 Northwest Biotherapeutics Inc Procedimiento para aumentar la presentación de clase I de antígenos exógenos por células dendríticas humanas
ATE317428T1 (de) * 2001-01-15 2006-02-15 Idm Immuno Designed Molecules Verfahren zur herstellung von submikropartikel- suspensionen pharmazeutischer substanzen
AU2002326463A1 (en) * 2001-07-25 2003-02-17 Northwest Biotherapeutics, Inc. Methods and apparatus for enrichment and culture of monocytic dendritic cell precursors

Also Published As

Publication number Publication date
AU2008221592B2 (en) 2012-12-20
IL160720A0 (en) 2004-08-31
WO2003022215A2 (en) 2003-03-20
JP2005505270A (ja) 2005-02-24
CN1636229B (zh) 2012-12-19
PT2322603T (pt) 2020-01-21
CA2459713A1 (en) 2003-03-20
US20080254064A1 (en) 2008-10-16
KR20050027163A (ko) 2005-03-17
JP5777956B2 (ja) 2015-09-16
JP2015107133A (ja) 2015-06-11
ES2598109T3 (es) 2017-01-25
AU2008221592A1 (en) 2008-10-16
JP6114768B2 (ja) 2017-04-12
KR20140116544A (ko) 2014-10-02
NZ531530A (en) 2007-01-26
CN102973928A (zh) 2013-03-20
BR0212545A (pt) 2005-01-18
IL160720A (en) 2012-05-31
NO338147B1 (no) 2016-08-01
EP2322603B1 (en) 2019-10-16
EP1441591A2 (en) 2004-08-04
US20050059151A1 (en) 2005-03-17
BRPI0212545A8 (pt) 2019-10-15
BRPI0212545B8 (pt) 2021-05-25
ES2766299T3 (es) 2020-06-12
PL372098A1 (en) 2005-07-11
JP2011188872A (ja) 2011-09-29
EP1441591B1 (en) 2016-06-29
EP2322603A1 (en) 2011-05-18
PT1441591T (pt) 2016-10-06
MXPA04002147A (es) 2005-03-07
IL219266A (en) 2014-02-27
DK1441591T3 (da) 2017-05-22
NO20040965L (no) 2004-04-23
CA2459713C (en) 2015-08-18
KR20110081341A (ko) 2011-07-13
EP1441591A4 (en) 2006-06-07
CN1636229A (zh) 2005-07-06
IL219266A0 (en) 2012-06-28
KR101803702B1 (ko) 2017-12-01
NO20151562A1 (no) 2015-11-16
WO2003022215A3 (en) 2003-11-13
HK1079989A1 (en) 2006-04-21
BRPI0212545B1 (pt) 2019-12-03
EP3653055A1 (en) 2020-05-20
CN102973928B (zh) 2019-03-15

Similar Documents

Publication Publication Date Title
DK2322603T3 (da) Sammensætninger og fremgangsmåder til aktivering af monocytiske dendritiske celler og t-celler for th1-respons
DK1148875T3 (da) Fremgangsmåder og sammensætninger til forögelse af antallet af hvide blodlegemer
DK3085779T3 (da) Fremgangsmåde til modifikation af eukaryotiske celler
DK1638999T3 (da) Sammensætninger og fremgangsmåder til øgning af knoglemineralisering
NO20013356D0 (no) Forsinkede tiksotropiske sementsammensetninger og fremgangsmåter
NO20000011D0 (no) Skumdempersammensetninger og fremgangsmåter
NO20013393L (no) Bronnsementeringsfremgangsmater og sammensetninger
DK1563069T3 (da) Sammensætninger og systemer til genregulering
DE60202043D1 (de) Simulationsvorrichtung
IS7520A (is) Pyrimidínonefnasambönd, samsetningar og aðferðir
NO20055347D0 (no) Blandinger og framgangsmate for WT1-spesifikk immunterapi
NO20034580L (no) Fremgangsmåte og reagenser for celletransplantasjon
NO20021786D0 (no) Skumdempningsfremgangsmåter og sammensetninger
DE50300080D1 (de) Selbsthaftende additionsvernetzende Siliconzusammensetzungen
DK1601744T3 (da) Forgasningsapparat og fremgangsmåde
DE60204749D1 (de) Abtast- und Halteschaltung
DK1355936T3 (da) Polymerkonjugater af neublastin og fremgangsmåder til anvendelse af samme
DE60219570D1 (de) Simulationsvorrichtung
DK1337228T3 (da) Sammensætninger til fjernelse af human cerumen
DE60328365D1 (de) Zusammensetzungen enthaltend nicht-vernetzte polysiloxane
DE60130187D1 (de) Strahlenhärtbare Siliconzusammensetzungen
DE60216645D1 (de) Antiulcus pflanzenzusammensetzung(en)
DK1484056T3 (da) Sammensætninger med langsom frigivelse og fremgangsmåde til fremstilling af disse
DE60308622D1 (de) Leistungsschalter
DK1372652T3 (da) Kombination af docetaxel og flavopiridol